To Cite:
Mi
Y, Gao
Y T, Jiao
X L, Guo
H, Liu
T, et al. The Role of Interleukin-28b Gene Polymorphisms in Chinese Patients With Chronic Hepatitis C Treated With Pegylated Interferon and Ribavirin,
Hepat Mon.
2014
; 14(8):e18793.
doi: 10.5812/hepatmon.18793.
2.
Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002; 36(5 Suppl 1)-46[DOI][PubMed]
3.
Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of Liver D. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009; 49(4): 1335-74[DOI][PubMed]
4.
Zeuzem S,
Berg T,
Moeller B,
Hinrichsen H,
Mauss S,
Wedemeyer H,
et al.
Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat. 2009; 16(2): 75-90[DOI][PubMed]
5.
Manns MP,
McHutchison JG,
Gordon SC,
Rustgi VK,
Shiffman M,
Reindollar R,
et al.
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001; 358(9286): 958-65[PubMed]
6.
Fried MW,
Shiffman ML,
Reddy KR,
Smith C,
Marinos G,
Goncales FL, Jr,
et al.
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347(13): 975-82[DOI][PubMed]
7.
Rauch A,
Kutalik Z,
Descombes P,
Cai T,
Di Iulio J,
Mueller T,
et al.
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010; 138(4): 1338-45[DOI][PubMed]
8.
Suppiah V,
Moldovan M,
Ahlenstiel G,
Berg T,
Weltman M,
Abate ML,
et al.
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009; 41(10): 1100-4[DOI][PubMed]
9.
Tanaka Y,
Nishida N,
Sugiyama M,
Kurosaki M,
Matsuura K,
Sakamoto N,
et al.
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009; 41(10): 1105-9[DOI][PubMed]
10.
Ochi H,
Maekawa T,
Abe H,
Hayashida Y,
Nakano R,
Imamura M,
et al.
IL-28B predicts response to chronic hepatitis C therapy--fine-mapping and replication study in Asian populations. J Gen Virol. 2011; 92: 1071-81[DOI][PubMed]
11.
Lyoo K,
Song MJ,
Hur W,
Choi JE,
Hong SW,
Kim CW,
et al.
Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin. J Clin Virol. 2011; 52(4): 363-6[DOI][PubMed]
12.
Venegas M, Villanueva RA, Gonzalez K, Brahm J. IL28B polymorphisms associated with therapy response in Chilean chronic hepatitis C patients. World J Gastroenterol. 2011; 17(31): 3636-9[DOI][PubMed]
13.
Hsu CS,
Hsu SJ,
Chen HC,
Tseng TC,
Liu CH,
Niu WF,
et al.
Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy. Proc Natl Acad Sci U S A. 2011; 108(9): 3719-24[DOI][PubMed]
14.
Chen JY,
Lin CY,
Wang CM,
Lin YT,
Kuo SN,
Shiu CF,
et al.
IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-alpha plus ribavirin therapy in Taiwanese chronic HCV infection. Genes Immun. 2011; 12(4): 300-9[DOI][PubMed]
15.
Sinn DH,
Kim YJ,
Lee ST,
Gwak GY,
Choi MS,
Lee JH,
et al.
Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in Asian patients. J Gastroenterol Hepatol. 2011; 26(9): 1374-9[DOI][PubMed]
16.
Sievert W,
Altraif I,
Razavi HA,
Abdo A,
Ahmed EA,
Alomair A,
et al.
A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int. 2011; 31 Suppl 2: 61-80[DOI][PubMed]
17.
Park JC, Kim JM, Kwon OJ, Lee KR, Chai YG, Oh HB. Development and clinical evaluation of a microarray for hepatitis C virus genotyping. J Virol Methods. 2010; 163(2): 269-75[DOI][PubMed]
18.
Ito K,
Higami K,
Masaki N,
Sugiyama M,
Mukaide M,
Saito H,
et al.
The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukin-28B. J Clin Microbiol. 2011; 49(5): 1853-60[DOI][PubMed]
19.
Ridruejo E,
Solano A,
Marciano S,
Galdame O,
Adrover R,
Cocozzella D,
et al.
Genetic variation in interleukin-28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin. Ann Hepatol. 2011; 10(4): 452-7[PubMed]
20.
Imazeki F, Yokosuka O, Omata M. Impact of IL-28B SNPs on control of hepatitis C virus infection: a genome-wide association study. Expert Rev Anti Infect Ther. 2010; 8(5): 497-9[DOI][PubMed]
21.
Idrees M, Riazuddin S. A study of best positive predictors for sustained virologic response to interferon alpha plus ribavirin therapy in naive chronic hepatitis C patients. BMC Gastroenterol. 2009; 9: 5[DOI][PubMed]
22.
Weich V,
Herrmann E,
Chung TL,
Sarrazin C,
Hinrichsen H,
Buggisch P,
et al.
The determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alpha based therapy in HCV type-1 infection. J Gastroenterol. 2011; 46(12): 1427-36[DOI][PubMed]
23.
Hofmann WP, Zeuzem S. A new standard of care for the treatment of chronic HCV infection. Nat Rev Gastroenterol Hepatol. 2011; 8(5): 257-64[DOI][PubMed]
24.
Tsubota A, Fujise K, Namiki Y, Tada N. Peginterferon and ribavirin treatment for hepatitis C virus infection. World J Gastroenterol. 2011; 17(4): 419-32[DOI][PubMed]
Readers' Comments